12:02 PM EDT, 04/28/2025 (MT Newswires) -- iRhythm Technologies ( IRTC ) said Monday that its Zio long-term continuous monitoring service, or LTCM, a patch-based ECG monitoring device, showed the highest diagnostic yield vs. other ambulatory cardiac monitoring methods and LTCM services during the AVALON study.

The study, which analyzed data from a cohort of 428,707 commercially insured patients, found that new arrhythmia diagnosis, within the first 90 days, was highest for Zio LTCM service at 26.5%, followed by non-iRhythm long-term continuous monitoring at 18.4%, ambulatory event monitoring at 17% and Holter monitoring at 14.7%, according to the announcement.

The study data also showed that the Zio LTCM service "was associated with a lower likelihood of cardiovascular events compared to other ambulatory cardiac monitoring modalities and all other LTCM services," the company said.

The data was presented at the Heart Rhythm Society's annual meeting held between April 24 and April 27.

Price: 105.24, Change: -0.75, Percent Change: -0.71